CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 85 enrolled
Drug / intervention
Standard Care +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03354143
NCT03354143Phase 2Completed
CompareCT.gov

Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)

University of Texas Southwestern Medical Center·interventional·Posted Nov 27, 2017·Updated Jul 2, 2025

In Brief

A Phase 2 clinical trial evaluating Standard Care and Intensive Treatment for Hypertension. Completed, enrolled 85 participants across 1 site.

Detailed Summary

The aim of this study is to determine if lowering blood pressure using FDA approved medication (antihypertensive drugs) alters brain pulsatility and reduces brain amyloid beta protein accumulation in older adults. Amyloid beta protein is high in the brain of older adults with Alzheimer's disease. Hypertension may increase brain amyloid beta protein accumulation and affect memory and thinking ability in older adults. However, whether lowering blood pressure reduces brain amyloid beta protein and improves brain function is inconclusive. The investigators hypothesize that treating high blood pressure alters brain pulsatility, which in turn reduces brain amyloid beta protein accumulation and improves brain structure and function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
CollaboratorsTexas Health Resources, Michigan State University, National Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 27, 2017
Enrollment StartApr 10, 2018
Primary CompletionJan 22, 2024
Study CompletionMar 30, 2024
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 8.6 years ago

Interventions

Standard Careother

Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.

Intensive Treatmentother

Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.